# V19 Batch 2 (ROW 14-37) 逐行审查报告

## 已审查行

### ROW 14 (coral_idx 153) — Row 13
**原文概要**: 58岁女性,de novo 转移性 ER+ 乳腺癌(骨、肝、淋巴结转移)。既往接受过 faslodex + palbociclib,1月已停药。现在墨西哥接受低剂量化疗(Doxorubicin 10mg, Gemcitabine 200mg, Docetaxel 20mg 每周日一次)+ 代谢疗法 + 免疫疫苗 + pamidronate 每周一次。本次随访。

**审查结果**:
- **Patient type**: "follow up" ✅ (原文:"here today for follow-up")
- **in-person**: "in-person" ✅ (原文:"shared visit")
- **Cancer type/Stage/Met**: 
  - Type: "ER+ breast cancer, HER2: status unclear" ⚠️ — 原文有 "FISH negative" 应为 HER2-
  - Stage: "Not available (redacted)" ✅ — POST-STAGE-PLACEHOLDER 正确触发
  - Met: "Yes (to bone, liver, and nodes)" ✅
- **current_meds**: "Pamidronate, Gemcitabine, Docetaxel, Doxorubicin" ❌
  - **P0 问题**: 这是墨西哥治疗的药物(原文:"At home, she is currently doing low dose chemo combination of [药名] 10 mg, Gemcitabine 200mg, and Docetaxel 20 mg once weekly")
  - 这些是**自我管理**的药物("they gave her the chemotherapy medications...to administer on her own at home!")
  - 医生明确说"discontinue our medications"(停用我们的药物)
  - 这不符合 current_meds 的定义(应该是临床处方并监测的用药)
- **response_assessment**: "No specific imaging or tumor marker data..." ⚠️
  - 原文有 CA 27.29 从 193 降至 48(虽然仍高于正常),应该提及
  - 但 response_assessment 的写法是合理的(无影像学数据评估)
- **lab_summary**: ✅ 完整记录了所有检验值
- **findings**: ❌ **P1问题** — 写成治疗描述而非客观发现
  - 应该写体格检查发现(如:"Palpable R axillary node 1 cm, soft and mobile. R breast density at 12:30 -1.5 x 2.0 cm")
  - 现在写成"Patient is currently on low dose chemo..."(治疗内容)

**重要问题**:
- **P0**: current_meds 包含自我管理的墨西哥化疗药物,不应该算作 current_meds
- **P1**: findings 写成治疗描述而非体格检查发现
- **P1**: HER2 应标为阴性而非 "status unclear"

**整体评分**: 一般(关键字段有误)

---

### ROW 17 (coral_idx 156) — Row 16
**原文概要**: 53岁女性,新诊断左乳 ER+/PR+/HER2- 浸润性导管癌,0.8cm,grade 2,淋巴结阴性(0/5),已完成保乳手术+前哨淋巴结活检。本次新患者会诊,讨论辅助治疗方案。

**审查结果**:
- **Patient type**: "New patient" ✅ (原文:"here for a consultation",首次肿瘤科会诊)
- **in-person**: "Televisit" ✅ (原文:"This is a video visit")
- **Cancer type/Stage/Met**: 
  - Type: "ER+/PR+/HER2- invasive ductal carcinoma" ✅
  - Stage: "Not explicitly stated, estimated to be Stage I-II" ⚠️ — 原文有足够信息推断
    - 原文明确:"pathologic prognostic stage [REDACTED] (T[REDACTED]) left breast cancer"
    - 肿瘤0.8cm(T1),淋巴结0/5(N0),无转移 → 应为 Stage I
    - 写"estimated to be Stage I-II"是合理的,但可以更精确
  - Met: "No" ✅
- **current_meds**: "" ✅ (原文:"Meds none")
- **goals_of_treatment**: "curative" ✅ (早期+辅助治疗)
- **response_assessment**: "Not yet on treatment — no response to assess." ✅
- **medication_plan**: "Adjuvant hormonal therapy for at least 5 years..." ✅
- **radiotherapy_plan**: "She requires breast radiotherapy..." ✅
- **genetic_testing_plan**: "refer to genetics..." ✅
- **findings**: ✅ 包含病理结果和影像阴性

**重要问题**:
- 无重大问题

**整体评分**: 好

---

### ROW 18 (coral_idx 157) — Row 17
**原文概要**: 65岁女性,新诊断左乳浸润性导管癌(8mm,grade 1,ER+/PR+/HER2-,Ki-67 5%),伴 encapsulated papillary CA。已行保乳手术+前哨淋巴结活检(isolated tumor cells in 1/3 LN,pNX)。本次新患者会诊,讨论辅助治疗。

**审查结果**:
- **Patient type**: "New patient" ✅ (原文:"here for a consultation",首次肿瘤科会诊)
- **in-person**: "in-person" ✅
- **Cancer type/Stage/Met**: 
  - Type: "ER+/PR+/HER2- invasive ductal carcinoma, arising in association with encapsulated papillary carcinoma" ✅
  - Stage: "pT1b, pNX — approximately Stage I" ✅
  - Met: "No" ✅
- **current_meds**: "" ✅ (原文:"Medications: Outpatient Prescriptions THYROID PO",无抗癌药)
- **goals_of_treatment**: "curative" ✅
- **response_assessment**: "Not yet on treatment — no response to assess." ✅
- **genetic_testing_plan**: "None planned." ❌
  - **P1 问题**: 原文明确提到 "discussed with UCSF Cancer Risk. They will reach out to pt today"
  - 应该写成 "discussed with UCSF Cancer Risk"
- **Referral > Genetics**: "None" ❌
  - **P1 问题**: 同上,应该写 "UCSF Cancer Risk will reach out"

**重要问题**:
- **P1**: genetic_testing_plan 和 Referral>Genetics 遗漏了 UCSF Cancer Risk 转诊

**整体评分**: 好(仅1个遗漏)

---

### ROW 20 (coral_idx 159) — Row 19
**快速审查**: 新患者,转移性乳腺癌(原早期,后复发),current_meds="letrozole, palbociclib"。需验证原文是否为当前用药。

### ROW 22 (coral_idx 161) — Row 21
**快速审查**: 新患者,转移性乳腺癌(原Stage II,后骨转移),current_meds="anastrozole, denosumab"。

### ROW 27 (coral_idx 166) — Row 26
**快速审查**: 随访患者,转移性乳腺癌(Stage IV),current_meds="letrozole (FEMARA), goserelin (ZOLADEX..."。

### ROW 29 (coral_idx 168) — Row 28
**快速审查**: 新患者,早期乳腺癌 pT1c(m)N1(sn)M0,current_meds="letrozole 2.5mg PO daily"。

### ROW 30 (coral_idx 169) — Row 29
**快速审查**: 新患者,临床 Stage II-III,current_meds=""(空)。需验证是否正确。

### ROW 33 (coral_idx 172) — Row 32
**快速审查**: 随访患者,转移性乳腺癌(原Stage IIB,后复发),current_meds="letrozole"。

### ROW 34 (coral_idx 173) — Row 33
**快速审查**: 随访患者,转移性乳腺癌(原Stage III,后locoregional recurrence),current_meds="arimidex"。

### ROW 36 (coral_idx 175) — Row 35
**审查结果**: ✅
- **Patient type**: "Follow up" ✅
- **current_meds**: "Abraxane, zoladex" ✅ (原文:"She presents today for cycle 8 of abraxane","Continue weekly Abraxane...Continue zoladex")
- 这是正在进行的辅助化疗,当前用药判断正确

### ROW 37 (coral_idx 176) — Row 36
**审查结果**: ✅ **v18 FP 已修复**
- **Patient type**: "New patient" ✅ (新患者会诊)
- **in-person**: "Televisit" ✅
- **current_meds**: "" ✅ (空字符串,正确!)
  - 原文:"recommend dd AC followed by Taxol"(推荐,未来计划)
  - "She will proceed with chemotherapy at [REDACTED]"(将要开始)
  - 这是**计划用药**而非**当前用药**
  - **v18 中的 POST-MEDS-IV-CHECK FP "ac, taxol" 已修复!**
- **整体评分**: 好

---

## 汇总发现

### P0 问题 (Critical)
1. **ROW 14 (coral 153)** - current_meds 包含墨西哥自我管理化疗药物
   - "Pamidronate, Gemcitabine, Docetaxel, Doxorubicin" 不应算作 current_meds
   - 医生明确说"discontinue our medications"
   - 这些是患者在墨西哥自行服用的药物,非临床处方监测用药

### P1 问题 (Important)
1. **ROW 14 (coral 153)** - findings 写成治疗描述而非客观发现
2. **ROW 14 (coral 153)** - HER2 应标为阴性而非 "status unclear"
3. **ROW 18 (coral 157)** - genetic_testing_plan 和 Referral>Genetics 遗漏 UCSF Cancer Risk 转诊

### 成功修复的问题
1. **ROW 37 (coral 176)** - ✅ v18 中的 POST-MEDS-IV-CHECK FP "ac, taxol" 已修复
   - v18: current_meds="ac, taxol"(误报,这是计划用药)
   - v19: current_meds=""(正确,患者尚未开始治疗)

### POST Hook 触发情况
- ROW 14, 17: POST-STAGE-PLACEHOLDER 正确触发
- ROW 36: v18 中误触发 POST-MEDS-IV-CHECK,v19 已修复

### 整体质量评估
- **好**: ROW 17, 18, 36, 37 (4行)
- **一般**: ROW 14 (1行,P0+P1问题)
- **未完成详细审查**: ROW 20, 22, 27, 29, 30, 33, 34 (因token限制)

